Novo Nordisk

2024 - 2 - 5

Novo Nordisk Expands Production Capabilities with $11bn Catalent Deal

Catalent Catalent

Novo Nordisk's parent company acquires three manufacturing sites to enhance drug supply, focusing on obesity and diabetes medications.

Novo Nordisk, a leading Danish drugmaker, has made a significant move in the pharmaceutical industry by striking an $11 billion deal to acquire three manufacturing sites. These facilities will enable Novo Nordisk to expand its production capacity, with a primary focus on boosting the supply of its weight-loss drug, Wegovy, and diabetes medication, Ozempic.

The deal, led by Novo Holdings, the controlling shareholder of Novo Nordisk, involves the purchase of Catalent, a provider of drug manufacturing services. This strategic acquisition is aimed at overcoming supply challenges and meeting the increasing demand for Novo Nordisk's popular medications.

The three manufacturing sites acquired by Novo Nordisk are specialized in the sterile filling of drugs and are strategically located in Italy, Belgium, and Indiana, USA. With a workforce of over 3,000 employees, these sites will play a crucial role in enhancing Novo Nordisk's production capabilities and ensuring a steady supply of essential medications.

Novo Nordisk's proactive approach to addressing supply issues through this multi-billion dollar deal reflects its commitment to innovation and meeting the healthcare needs of global communities. By strengthening its manufacturing capabilities, Novo Nordisk aims to continue providing high-quality and life-changing medications to patients worldwide.

Post cover
Image courtesy of "Financial Times"

Novo Nordisk strikes $11bn deal to expand production of weight ... (Financial Times)

Danish drugmaker to acquire three manufacturing sites as its controlling shareholder buys US company Catalent.

Post cover
Image courtesy of "MarketWatch"

Novo Nordisk to buy facilities to boost weight-loss drug supply (MarketWatch)

The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday said it's buying a provider of drug manufacturing for $16.5 billion.

Post cover
Image courtesy of "STAT"

Novo Holdings to purchase drug manufacturer Catalent for $16.5 ... (STAT)

The deal could help Novo Nordisk produce more of its wildly popular obesity drug Wegovy, as well as its diabetes medicine Ozempic.

Novo Nordisk To Acquire Three Catalent Manufacturing Sites From Novo Holdings (Nasdaq)

Novo Nordisk will acquire the three manufacturing sites for an upfront payment of $11 billion. The three manufacturing sites are specialised in the sterile filling of drugs and located in Italy, Belgium and Indiana, US. The sites employ more than 3,000 ...

Post cover
Image courtesy of "pharmaphorum"

Novo Nordisk tackles supply issues with $11bn Catalent deal (pharmaphorum)

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity therapy ...

Post cover
Image courtesy of "Yahoo Finance"

Novo Nordisk parent to buy Catalent for $11.5 billion to boost ... (Yahoo Finance)

Catalent, whose shares rose 12% to $61.50 in premarket trading, is the main supplier of fill-finish work, or filling and packaging syringes and injection ...

Post cover
Image courtesy of "Reuters"

Novo Nordisk parent to buy Catalent for $11.5 bln to boost Wegovy ... (Reuters)

Novo Holdings, parent of Novo Nordisk , will buy contract drugmaker Catalent for $11.5 billion in cash to help meet the strong demand for its popular ...

Post cover
Image courtesy of "CNBC"

Novo Nordisk parent to buy Catalent for $16.5 billion to expand ... (CNBC)

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Novo to acquire contract manufacturer Catalent for $16.5B (Endpoints News)

Catalent, a major player in the contract development and manufacturing world, is heavily involved in producing Novo Nordisk's top-selling obesity drug Wegovy, ...

Post cover
Image courtesy of "Investor's Business Daily"

Novo Nordisk To Up Production Capacity As Parent Buys Catalent (Investor's Business Daily)

NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.

Post cover
Image courtesy of "Investopedia"

Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal (Investopedia)

Catalent stock rose following news Novo Holdings, the parent of Wegovy maker Novo Nordisk, will buy the syringe maker for $16.5 billion in an all-cash deal.

Novo Nordisk's Parent Company to Acquire Catalent To Boost ... (Pharmaceutical Executive)

Novo Nordisk continues to make moves to improve the supply of popular weight loss drug Wegovy. The drugmaker's parent company, Novo Holdings, has agreed to ...

Post cover
Image courtesy of "FiercePharma"

Novo Holdings pays $16.5B to scoop up CDMO giant Catalent (FiercePharma)

Late last month, Novo Holdings' CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash.

Post cover
Image courtesy of "The Guardian"

Novo Nordisk parent buys US drug firm for $16.5bn to expand ... (The Guardian)

Novo Holdings is to buy the New Jersey-based pharmaceutical firm Catalent, and then immediately sell three of its sites for $11bn in US and Europe to Wegovy ...

Post cover
Image courtesy of "Bloomberg Law"

Goodwin, Skadden Lead $16.5 Billion Novo Nordisk Shareholder Buy (Bloomberg Law)

Goodwin Procter and Skadden, Arps, Slate, Meagher & Flom are aiding the deal that allows Novo Nordisk A/S to respond to demand for the drugs Wegovy and ...

Post cover
Image courtesy of "Reuters"

Fill-finish sites will help Novo Nordisk boost Wegovy, Ozempic ... (Reuters)

Novo Nordisk's acquisition of three fill-finish sites will help boost output of its popular Wegovy and Ozempic drugs, the CEO of its parent company Novo ...

Post cover
Image courtesy of "Genetic Engineering & Biotechnology News"

Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo ... (Genetic Engineering & Biotechnology News)

Novo Holdings, the asset manager of the foundation that controls Novo Nordisk, has agreed to acquire Catalent for $16.5 billion—with the buyer standing to ...

Post cover
Image courtesy of "The Washington Post"

Novo Nordisk buys manufacturing power as it seeks to ramp up ... (The Washington Post)

Novo Nordisk is acquiring three manufacturing sites from Catalent as it seeks to keep up with patient demand for weight-loss drug Wegovy.

Novo Holdings to buy contract drugmaker Catalent for $16.5B (BioPharma Dive)

The controlling shareholder of Novo Nordisk will take the CDMO private, while selling three Catalent factories to Novo Nordisk in a related $11 billion deal.

Post cover
Image courtesy of "The Wall Street Journal"

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar ... (The Wall Street Journal)

for $16.5 billion, including debt. In turn, Novo Holdings will flip three of the most critical Catalent plants to Novo Nordisk for $11 billion, which will help ...

Explore the last week